Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway

Lei Yong1 · Yunlong Ma2 · Bin Zhu1 · Xiao Liu1 · Peng Wang1 · Chen Liang1 · Guanping He1 · Zhigang Zhao1 · Zhongjun Liu1 · Xiaoguang Liu1

Received: 3 May 2018 / Accepted: 24 September 2018 / Published online: 28 September 2018
© The Author(s) 2018

Abstract
Purpose Our previous studies have reported the antitumor effect of oleandrin on osteosarcoma; however, its chemosensitizing effect in osteosarcoma treatment is still unknown. Therefore, we explored the sensitizing effects of oleandrin to cisplatin in osteosarcoma and investigated the potential mechanisms.

Methods After exposure to oleandrin and/or cisplatin, CCK-8 and colony formation assays, DAPI staining and flow cytometry were performed to detect cell proliferation and apoptosis in 143B, U-2OS and MG-63 osteosarcoma cells. The median-effect analysis was applied to evaluate the combined effect. Western blot was used to determine the expression of related proteins. Osteosarcoma xenografts and histological observations were applied to confirm the combined effect in vivo.

Results Compared with cisplatin or oleandrin alone, the combined treatment significantly inhibited cell proliferation and induced cell apoptosis. The median-effect analysis indicated a synergistic cytotoxic effect. The combined treatment downregulated Bcl-2 and upregulated Bax and cleaved caspase-3, -8 and -9. And the suppression of caspases reduced cell death. Furthermore, oleandrin alone or with cisplatin, activated the p38 MAPK/Elk-1 pathway. The inhibition of the p38 MAPK pathway increased cell viability and reduced apoptosis. In vivo, the combined treatment was also verified to significantly inhibit tumor growth, induce apoptosis and activate the p38 MAPK pathway.

Conclusions The combination of oleandrin with cisplatin exerts a synergistic antitumor effect in osteosarcoma, which relates to the activation of the p38 MAPK pathway.

Keywords Osteosarcoma · Cisplatin · Oleandrin · Synergistic effect · P38 MAPK

Introduction
Osteosarcoma is the most frequent primary malignant bone tumor and predominantly affects young adults and adolescents [1]. The 5-year overall survival rate has increased from <20% with surgery alone to 60–65% with the addition of chemotherapy [2]. However, recent decades have witnessed no further improvements in survival. In addition, drug-induced side effects and resistance limit the application of conventional chemotherapy [3]. Therefore, novel therapeutic agents and strategies with high potency are urgently needed.

Oleandrin (OLE), one type of polyphenolic cardiac glycoside extracted from the leaves of Nerium oleander L., has long been used to treat congestive heart failure by inhibiting Na+/K+-ATPase [4]. OLE exerts antitumor effects on several types of human tumor cells, including prostate adenocarcinoma, pancreatic cancer and glioma [5–7], but has no significant cytotoxicity against non-malignant cells [8]. Our previous studies reported that OLE has antitumor activity against osteosarcoma in vitro and does not induce the death of normal hFOB1.19 human osteoblast cells [9, 10]. These findings suggest that OLE may be an effective drug therapy for osteosarcoma.
Cisplatin (DDP), a first-line chemotherapeutic drug, is widely used to treat various tumors, including osteosarcoma. However, drug resistance and its main side effect of nephrotoxicity severely limit its therapeutic effect [3]. Recently, accumulating studies have demonstrated that OLE can potentially sensitize tumor cells to DDP. In two colon cancer cell lines HT29 and HCT116, the combination of OLE with DDP or oxaliplatin had additive or synergistic inhibitory effects [11]. In A549 human lung cancer cells, an extract from the leaves of *N. oleander* showed moderate synergism when administered after DDP [12]. The combination of Anvirzel, a *N. oleander* extract that is mainly composed of OLE and its deglycosylated metabolite oleandrinigen, with DDP exerted a synergistic effect in various cancer cells [13]. However, no report has revealed whether OLE increases the sensitivity of osteosarcoma cells to DDP.

p38 mitogen-activated protein kinase (MAPK) pathway, a key member in the MAPK superfamily, regulates a variety of cellular responses to stress and inflammation. Two major groups of substrate regulated by p38 MAPK phosphorylation are transcription factors, such as p53, activating transcription factor 2 (ATF2), myocyte-specific enhancer factor 2 (MEF2) and ETS transcription factor (Elk-1); and protein kinases like MAPK-activated kinase 2 (MK2) [14]. Evidence suggests that the suppression of the p38 MAPK pathway relates to the development of DDP resistance [15, 16]. The cardiac glycosides bufalin and ouabain have been shown to activate p38 MAPK in human umbilical vein endothelial cells (HUVECs) and breast cancer cells, respectively [17, 18]. Whether OLE activates p38 MAPK is unknown, and whether the potential activation of p38 MAPK is involved in the combined effect of DDP and OLE in osteosarcoma needs to be clarified.

The present study had the following aims: (1) to determine the potential synergistic antitumor effect of DDP and OLE on osteosarcoma cells in vitro; (2) to explore the underlying mechanisms involved in the combined effect; and (3) to further evaluate the combined effect on osteosarcoma growth in vivo.

**Materials and methods**

**Reagents and antibodies**

The following reagents and antibodies were used in this study: OLE, SB203580 (Sigma-Aldrich Chemical Co., St. Louis, MO, USA); DDP (Jiangsu Hanson Pharmaceutical Ltd., Jiangsu, China); Z-VAD-FMK (Beyotime Biotech Ltd., Nanjing, China); antibodies against B-cell lymphoma protein 2 (Bcl-2), Bcl-2-associated X protein (Bax), cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, phospho-p38 MAPK (P-p38), p38 MAPK, phospho-Elk-1 (P-Elk-1) and Elk-1 (Cell Signaling Technology, Beverly, MA, USA); and antibody against β-actin (CWBIO Biotech Ltd., Beijing, China).

**Cell culture**

The MG-63 and 143B cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The source and culture method of U-2OS cells were described previously [9]. The human kidney-2 (HK-2) immortalized human proximal tubular cells were kindly provided by Dr. Yue Wang from Peking University Third Hospital. MG-63 and 143B cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/high glucose, and HK-2 cells were cultured in DMEM/F-12 medium (HyClone, Logan, UT, USA). All media contained 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) and 1% penicillin–streptomycin (10,000 U/mL) (Gibco). The cells were incubated at 37 °C in a humidified 5% CO₂ incubator.

**Cell viability assay**

Five thousand cells per well were seeded into 96-well plates, incubated overnight and then treated with DDP and/or OLE for 24 h. Then, the cells were incubated with 10 µL of cell counting kit-8 (CCK-8) reagent (Dojindo Laboratories, Kumamoto, Japan) for 2 h. An automatic ELISA plate reader was used to measure the absorbance at 450 nm. The surviving fraction was calculated as follows: (%) = [OD (treatment)-OD (blank)]/[OD (control)-OD (blank)]×100%. The experiments were repeated three times with at least triplicate wells for each concentration.

**Combination analysis**

The combined effect of DDP and OLE was evaluated based on the median-effect equation proposed by Chou and Talalay [19] and quantified using the combination index (CI), where CI < 1, CI = 1 and CI > 1 indicate synergy, an additive effect and antagonism, respectively. The median-effect equation: \( \frac{fa}{fu} = \frac{D \cdot Dm}{m \cdot Dm} \), where \( D \) is the concentration of a drug, \( fa \) is the cell fraction affected by \( D \) (i.e., percentage inhibition/100), and \( fu \) is the fraction unaffected (i.e., \( 1 - fa \)). \( Dm \) is the median-effect dose that inhibits cells under study by 50%, and \( m \) is the coefficient signifying the shape of the dose–effect relationship. The values of \( fa \) were obtained from CCK-8 assays, where cells were treated with OLE, DDP and OLE + DDP at fixed ratios according to the equation. Then, putting \( fa \) values into the median-effect equation can generate the corresponding doses of cisplatin/oleandrin alone or in combination at any \( fa \). Finally, for each \( fa \), a corresponding CI was produced as follows: CI = \( \frac{(D_1)^f}{(D_0)^f} + \frac{(D_2)^f(D_1)^g}{(D_0)^f} + \frac{(D_1)^f(D_2)^g}{(D_0)^f} \), where \( (D_0)^f \) and
\((D)_2\) are the doses of drug 1 combined with drug 2 that are needed to produce \(fa\), and \((Df)_1\) and \((Df)_2\) are the doses of the drugs alone to produce the same \(fa\). In cancer treatment, a combination is explored to achieve maximal effects; therefore, \(fa < 0.5\) was deemed irrelevant. All these calculating operations were performed with the CalcuSyn software version 2.1 (BIOSOFT, Great Shelford, Cambridge, UK).

**Colony formation assay**

Two thousand cells per well were plated into 6-well plates and allowed to adhere for 24 h. Then, the cells were treated with control medium, DDP, OLE or DDP + OLE for 10 days. After incubation, the colonies were washed with 1× phosphate-buffered saline (PBS), fixed with 4% ice-cold paraformaldehyde for 15 min and stained with 0.1% crystal violet, and the colony numbers were counted manually. Then, the dye was washed away, and the number of colonies that contained more than 50 cells was determined.

**4′,6-Diamidino-2-phenylindole (DAPI) staining**

The cells were seeded in 24-well plates and treated as indicated above for 24 h. After treatment, the cells were washed with 1× PBS and fixed with 4% ice-cold paraformaldehyde for 15 min. Then, the cells were incubated with a DAPI staining solution (Beyotime) for 5 min at room temperature in the dark. A fluorescence microscope (Leica DM3000, Frankfurt, Germany) was used to observe and image cell nuclei at a 100× magnification.

**Annexin V-FITC/propidium iodide (PI) apoptosis assay**

The cells were seeded into six-well plates and adhered overnight. Then, the cells were treated as described above. Subsequently, the cells were trypsinized and harvested in 1× PBS. According to the protocol in the Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, Franklin Lakes, NJ, USA), the cells were suspended in 1× Annexin V binding buffer and stained with Annexin V-FITC and PI at room temperature for 5 min in the dark. Finally, the cells were analyzed by a CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA).

**Western blotting assay**

The cells were lysed using the Total Protein Extraction Kit (Applygen Technologies Inc., Beijing, China), and the BCA Protein Assay Kit (Applygen Technologies Inc.) was applied to measure protein concentrations. Equal amounts of protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes. Then, the membranes were blocked with 5% bovine serum albumin at room temperature for 1 h and incubated with the primary antibodies overnight at 4 °C. The next day, after washing with Tris-buffered saline with Tween 20 (TBST), the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 1 h. The proteins were visualized by enhanced chemiluminescence (ECL) (Millipore Corp., Billerica, MA, USA) according to the manufacturer’s protocol.

**Nude mouse xenograft studies**

BALB/c nu/nu mice (Beijing HFK Bio-Technology Co., Ltd, Beijing, China) were maintained under specific pathogen-free conditions in the Department of Laboratory Animal Science of Peking University Health Science Center. Experimental procedures involving the animals were approved by the Peking University Institutional Review Board and performed in accordance with the approved guidelines. A total of \(1 \times 10^6\) 143B cells were suspended in 100 µL of PBS and injected subcutaneously into the dorsal right flank of BALB/c nu/nu mice (aged 4 weeks and weighing approximately 20 g). When the tumor volume reached approximately 150 mm³, the mice were randomly divided into four groups (six mice/group) and treated with drugs by intraperitoneal injection every two days as follows: (1) control group (physiological saline, 100 µL); (2) DDP group (1.5 mg/kg body weight); (3) OLE group (0.3 mg/kg body weight); and (4) DDP + OLE group (DDP, 1.5 mg/kg body weight and OLE, 0.3 mg/kg body weight). The animals were treated for 16 days. The body weight and tumor size were measured every 3 days, and the tumor volumes were calculated by the following formula: \(L \times W^2/2\) (\(L\), long diameter of the tumor; \(W\), short diameter of the tumor).

**Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining**

A TUNEL assay kit (Roche Diagnostics, Mannheim, Germany) was used to detect DNA fragmentation according to the manufacturer’s instructions. Briefly, the sections were deparaffinized, hydrated and incubated with proteinase K for 15 min at room temperature, followed by incubation with the TUNEL reaction mixture. TdT labeling was visualized by an HRP-conjugated Fab fragment.

**Immunohistochemical staining**

The xenografts were excised after the mice were killed and used to prepare formalin-fixed paraffin-embedded tissue sections. An EnVision two-step staining method was performed.
Briefly, after dewaxing in xylene and rehydration in a gradient of ethanol concentrations before antigen retrieval, the sections were incubated with a caspase-3 (1:1000) antibody overnight at 4 °C. Then, the sections were washed with PBS and incubated with an IgG-HRP polymer (CW BIO) and the diaminobenzidine substrate. Staining was scored according to the product of the intensity (0—no staining; 1—weak; 2—moderate; and 3—strong) and the percentage of positive staining (0, 0%; 1, 25%; 2, 26–50%; 3, 51–75%; and 4, 76–100%). The expression level of caspase-3 was defined as −, +, ++ and +++ based on the median staining score.

**Statistical analysis**

The data were analyzed by IBM SPSS Statistics 20.0 software (IBM, Armonk, NY, USA), and the results are expressed as the mean ± standard deviation (SD). The statistical analyses of the cell surviving fraction, half maximal inhibitory concentration (IC_{50}), CI and DRI were performed using Student’s t test. The statistical analyses for colony formation and apoptosis rates were conducted using one-way analysis of variance (ANOVA), followed by Dunnett’s t test to compare multiple treatment groups with the control group or the combined group. Differences were considered significant at p < 0.05.

**Results**

**The combination of DDP with OLE promotes cytotoxicity in osteosarcoma cells but not kidney cells**

To determine the cytotoxic effects of the drugs on cell viability, CCK-8 assays were conducted. As shown in Fig. 1a and Table 1, U-2OS and MG-63 cells were more sensitive to OLE than 143B cells (the IC_{50} values of OLE for U-2OS, MG-63 and 143B cells at 24 h were 45.84 ± 1.02, 51.55 ± 1.73 and 103.57 ± 4.48 nM, respectively). Conversely, U-2OS and MG-63 cells were more resistant to DDP than 143B cells (the IC_{50} values of DDP for 143B, U-2OS and MG-63 cells were 10 ± 0.00, 10 ± 0.00 and 10 ± 0.00 µM, respectively). We selected these combination doses for further studies.

To assess whether the combined effect of DDP and OLE represented synergism, we calculated the CI values based on the median-effect equation. The fa-CI plot demonstrated that the CI values were all lower than 1 (0.4–0.8) in the three osteosarcoma cell lines when fa ≥ 0.50, suggesting a synergistic antitumor effect of DDP and OLE (CI values at fa_{0.50} vs. 1.00, all p < 0.05; CI values at fa_{0.75} vs. 1.00, all p < 0.01; and CI values at fa_{0.90} vs. 1.00, all p < 0.001; Fig. 1h; Table 2). CI values of 0.51, 0.73 and 0.43 were obtained from the combination of 40 nM OLE with 5 µM DDP in 143B cells, 10 µM DDP in U-2OS cells and 20 µM DDP in MG-63 cells, respectively. We selected these combination doses for further studies.

**The combination of DDP with OLE enhances apoptosis in osteosarcoma cells**

DDP exerts cytotoxicity mainly through inducing apoptosis. Next, we tested whether the enhanced cytotoxicity of the combined therapy could be attributed to cell apoptosis. Figure 1i shows the cell shrinkage after exposure to the monotherapies and the combined therapy; the combined group exhibited the most significant morphological changes. DAPI staining showed the appearance of chromatin condensation and DNA fragmentation in all three treatment groups. Similar to the morphological changes, cells

© Springer
Fig. 1 The cytotoxic effects of oleandrin (OLE) and/or cisplatin (DDP). a The surviving fractions of 143B, U-2OS and MG-63 osteosarcoma cells after 24 h of OLE treatment at continuous concentrations (0–80 nM).
b–d The surviving fractions of 143B, U-2OS and MG-63 cells after treatment with continuous concentrations of DDP (143B, 0–10 µM; U-2OS, 0–20 µM; MG-63, 0–40 µM) and DDP + OLE for 24 h at fixed ratios (143B, 1:125; U-2OS, 1:250; and MG-63, 1:500). e The number of colonies in 143B, U-2OS and MG-63 cells after 24 h of exposure to DDP and/or OLE (143B, DDP 5 µM; U-2OS, DDP 10 µM; MG-63, DDP 20 µM; OLE 40 nM). f The surviving fractions of HK-2 normal human kidney cells after exposure to OLE (0–1000 nM) for 24 h. g The surviving fraction of HK-2 cells after treatment with DDP and DDP + OLE for 24 h (DDP: 0–20 µM, OLE: 0–80 nM). h The combination index (CI) values calculated from each fraction affected (fa) post-treatment. i Representative phase contrast images showing changes in cell morphologies in the three osteosarcoma cell lines after treatment as above. j Representative fluorescence microscopy images showing changes in cell nuclei in the three osteosarcoma cell lines after treatment as above. Data are presented as the mean ± SD. Scale bar 100 µm. *p < 0.01, **p < 0.01 and ***p < 0.001

### Table 1 Growth inhibition by DDP and/or OLE in osteosarcoma cells

| Cell line | IC₅₀ of DDP (µM) | p value | IC₅₀ of OLE (nM) | p value |
|-----------|-----------------|---------|-----------------|---------|
|           | Alone           | Combination | Alone           | Combination |
| 143B      | 6.98 ± 0.33     | 2.61 ± 0.05 | 0.002           | 103.57 ± 4.48 | 20.88 ± 0.41 | < 0.001 |
| U-2OS     | 30.47 ± 1.47    | 6.61 ± 0.40 | < 0.001         | 45.84 ± 1.02  | 26.46 ± 1.61  | < 0.001 |
| MG-63     | 62.81 ± 2.63    | 6.40 ± 0.80 | < 0.001         | 51.55 ± 1.73  | 12.80 ± 1.59  | < 0.001 |

### Table 2 The combination index (CI) values for the combination of DDP with OLE in osteosarcoma cells

| Cell line | CI at fa₀.₅₀ | CI at fa₀.₇₅ | CI at fa₀.₉₀ | Interpretation |
|-----------|--------------|--------------|--------------|----------------|
| 143B      | 0.58 ± 0.01***| 0.50 ± 0.01***| 0.44 ± 0.01***| Synergism      |
| U-2OS     | 0.80 ± 0.07*  | 0.67 ± 0.03** | 0.58 ± 0.02** | Synergism      |
| MG-63     | 0.35 ± 0.05** | 0.38 ± 0.04** | 0.42 ± 0.04** | Synergism      |

†p < 0.05, **p < 0.01, and ***p < 0.001 (one-sample, two-tailed t test compared with 1.00)
exposed to the combined treatment appeared to exhibit more severe DNA damage (Fig. 1j). In addition, flow cytometry analysis showed that the apoptosis rate of 143B cells in the combined group was 17.74%, which was significantly higher than the 1.67% observed in the control group, 8.51% in the DDP group and 9.10% in the OLE group (control group, DDP group and OLE group vs. combined group, all p < 0.01; Fig. 2a, b). The apoptosis rates of U-2OS cells in the control group, DDP group, OLE group and combined group were 1.69%, 6.19%, 7.72% and 15.18%, respectively (control group, DDP group and OLE group vs. combined group, all p < 0.001; Fig. 2a, b). Additionally, the apoptosis rates of MG-63 cells in the above four groups were 1.83%, 12.23%, 8.26% and 19.40%, respectively (control group, DDP group and OLE group vs. combined group, all p < 0.01; Fig. 2a, b).

The combination of DDP with OLE increases the activation of both intrinsic and extrinsic apoptotic pathways in osteosarcoma cells

There are two main apoptotic pathways induced by cytotoxic agents: the intrinsic and extrinsic pathways. We detected apoptosis-related proteins, including Bcl-2, Bax, and caspase-3, 8 and 9 to determine which pathway was induced by the combined therapy. Caspase-3 is the common executioner caspase in both apoptotic pathways, while Bcl-2, Bax and caspase-9 are involved in the intrinsic apoptotic pathway, and caspase-8 plays a role in the extrinsic pathway. The results clearly indicated that the monotherapies and the combined therapy all activated caspase-3 and -8 and triggered the expression of Bax (Fig. 2c). Moreover, OLE and the combined treatment also obviously caused the upregulation of cleaved caspase-9 and the downregulation of Bcl-2, whereas DDP alone only slightly increased the activation of caspase-9 in 143B and U-2OS cells and did not alter the expression of Bcl-2 in any osteosarcoma cells (Fig. 2c). In terms of the expression levels of these proteins, the combined treatment significantly increased the levels of Bax and cleaved caspase-3, -8 and -9 and obviously decreased the level of Bcl-2 compared with the values observed for DDP or OLE alone (Fig. 2c). To confirm the role of cell apoptosis in the combined therapy, we added Z-VAD-FMK (a pan-caspase inhibitor) at a dose of 20 µM to pretreat combined group and found that cell viability was significantly enhanced (Fig. 2d).

OLE alone or in combination with DDP activates p38 MAPK and Elk-1

The p38 MAPK pathway plays a key role in the process of DDP-induced apoptosis. Western blot assays showed that OLE and the combined treatment activated p38 MAPK, while no activation of p38 MAPK was found after DDP treatment alone (Fig. 3a). Elk-1 is a transcription factor that can be activated by P-p38 MAPK. As shown in Fig. 3a, OLE alone or combined with DDP also upregulated the expression of P-Elk-1. Further, to verify the role of the p38 MAPK pathway in the enhanced apoptosis, cells were pretreated with the p38 MAPK inhibitor SB203580 (143B, 2 µM; U-2OS and MG-63, 10 µM) and then exposed to DDP + OLE treatment. The P-p38 MAPK expression was obviously suppressed (Fig. 3b) and the enhanced expression of P-Elk-1 in combined groups was also reduced by SB203580 (Fig. 3b). Meanwhile, CCK-8 assays showed that SB203580 significantly attenuated the cell cytotoxicity of the combined treatment (DDP + OLE group vs. DDP + OLE + SB203580 group in 143B, U-2OS and MG-63 cells, all p < 0.01; Fig. 3d, e).

OLE potentiates the antitumor activity of DDP in the osteosarcoma xenograft model

To confirm the in vitro findings, we further examined the in vivo effect of DDP and/or OLE. As shown in Fig. 4a, b, compared with the results obtained for the physiological saline treatment, the DDP treatment and the OLE treatment significantly suppressed the growth of the xenograft tumors (DDP group or OLE group vs. physiological saline group, all p < 0.01). The combination of DDP with OLE showed more efficient tumor suppression than DDP or OLE alone (physiological saline group, DDP group or OLE group vs. DDP + OLE group, p < 0.001, p < 0.001 and p < 0.05, respectively; Fig. 4a, b). In addition, DDP obviously reduced the weight of the mice, while OLE did not cause significant weight loss and DDP + OLE did not increase weight loss than DDP alone (Fig. 4c). TUNEL assays of xenograft tumors revealed more cell death in the DDP + OLE group than in the DDP or OLE group (Fig. 4d). Immunohistochemical quantitative analysis showed that the expression level of cleaved caspase-3 was higher in the DDP + OLE group than in the DDP or OLE group (Fig. 4d). And the western blot assay verified the activation of P-p38 MAPK in vivo after OLE or DDP + OLE treatment (Fig. 4e).

Discussion

The survival rate of osteosarcoma has reached a plateau in recent decades. Our previous studies found that OLE exerted antitumor effects on osteosarcoma cells by inhibiting the Wnt/β-catenin signaling pathway [9, 10]. In the present study, we demonstrated that OLE synergistically enhanced the inhibitory effect of DDP against osteosarcoma cells in vitro and in vivo by promoting cell apoptosis. In addition, OLE showed no obvious toxicity in normal human kidney
Fig. 2 Cell apoptosis induced by cisplatin (DDP) and/or oleandrin (OLE). a The apoptosis rates of 143B, U-2OS and MG-63 cells after treatment with DDP and/or OLE for 24 h (143B, DDP 5 µM; U-2OS, DDP 10 µM; MG-63, DDP 20 µM; OLE 40 nM). b The quantitative results of the apoptosis analysis of 143B, U-2OS and MG-63 cells after treatment as above. c The expression of Bcl-2, Bax and cleaved caspase-3, 8 and 9, as detected by western blots after treatment as above. d The effects of pretreatment (for 1 h) with a pan-caspase inhibitor Z-VAD-FMK (20 µM) on the cell viability of the DDP + OLE-treated (for 24 h) osteosarcoma cells. Data are presented as the mean ± SD. **p < 0.01 and ***p < 0.001
Then, cytochrome c mainly activate caspase-8 and -3 to induce the extrinsic apoptotic pathways, whereas DDP chiefly triggered the combined treatment activated both the intrinsic and extrinsic apoptotic pathways [24]. Our observations showed that OLE alone and the combined treatment activated both the intrinsic and extrinsic apoptotic pathways, whereas DDP chiefly triggered the extrinsic apoptotic pathway. Similarly, DDP is widely known to mainly activate caspase-8 and -3 to induce the extrinsic apoptotic pathway in tumor cells [21, 25] and OLE was demonstrated to induce both apoptotic pathways [10]. Our study demonstrated that the addition of OLE to DDP remarkably decreased the Bcl-2/Bax ratio and involved various caspases functioning together, thus enhancing cell apoptosis. And the distinct cell rescue effect by pan-caspase inhibitor Z-VAD-FMK in the combined group further verified the role of cell apoptosis in the combined effect of DDP and OLE.

Many factors act together to influence the sensitivity of cancer cells to DDP, including DDP uptake, DDP detoxification, repair of DNA damage, tolerance to unrepaired DNA and activity in apoptotic signal pathways [26]. Evidence has shown that the activation of the p38 MAPK pathway plays a role in the DDP-induced apoptosis [20]. Here we first reported that OLE activated the phosphorylation of p38 MAPK and found the phospho-p38 MAPK was involved in the enhanced apoptosis caused by combined treatment. As a type of stress-activated protein kinase pathway, the activation of the p38 MAPK pathway induces apoptosis in osteosarcoma, hepatocellular carcinoma and breast cancer [27–30]. Brozovic et al. found that human cervical carcinoma cells with DDP resistance displayed an apparently reduced activation of p38 MAPK [15]. Zhang et al. reported that the suppression of p38 MAPK activation by heat shock protein 27 (Hsp27) endowed mouse fibroblast cells with DDP resistance [16]. These studies suggested that p38 MAPK pathway might contribute to DDP resistance.

We observed that DDP alone did not cause activation of p38 MAPK in osteosarcoma cells, indicating that the osteosarcoma cells were resistant to DDP at this dose. We observed that p38 MAPK pathway might contribute to DDP resistance. We observed that DDP + OLE induced the activation of p38 MAPK and the P-p38 MAPK inhibition by SB203580 reduced the cytoxicity of the two drugs, suggesting that the p38 MAPK pathway played a partial role in the combined effects. In line with our findings, Weir et al. reported that curcumin induced apoptosis in cisplatin-resistant ovarian cancer cells through the activation of p38 MAPK and p53 [31]. Tripathi et al. found that the addition of fisetin, a flavonoid, to cisplatin increased the phosphorylation of p38 MAPK in human embryonal carcinoma cells and that the inhibition of p38 MAPK phosphorylation resulted in significant protection for the cells [21].

The phosphorylation of p38 MAPK further activates the downstream proteins to transmit signals. As a downstream substrate of phospho-p38 MAPK, Elk-1 is a transcription factor belongs to the ETS-domain family and involved in cell apoptosis. In squamous cell carcinoma, the inhibitor of DNA binding 3 (Id3) induced apoptosis through an Elk-1-caspase-8-dependent pathway [32]. In HaCaT Keratinocytes, the activation of Elk-1 mediated sodium arsenite-induced apoptosis by upregulating Bax expression [33]. In addition, Elk-1 has been reported to upregulate the expression of death receptor 5 (DR5), a transmembrane receptor that triggers the extrinsic apoptotic pathway, in breast cancer and lung cancer [34, 35]. In our study, we found that the combined treatment enhanced the phosphorylation of Elk-1.
and the induction of SB203580 into combined treatment attenuated the activation of Elk-1, suggesting Elk-1 was a key transcription factor influenced by P-p38 MAPK in the process of DDP + OLE-induced cell apoptosis.

Our in vivo data showed that the combined therapy exhibited more efficient tumor suppression than did the monotherapies. Similarly, OLE combined with temozolomide significantly improved survival time in glioma-bearing mice compared with temozolomide alone [7]. However, we found the combined effect was weaker in vivo than in vitro. The drug ratio plays a critical role in getting ideal therapeutic efficacy in combination studies. However,
not like in the in vitro study, it is hard to find an appropriate ratio in the in vivo study, which is time-consuming and costly [36]. Meanwhile, variable drug pharmacokinetic profiles further increase the difficulty to keep a satisfying drug ratio [37]. In our study, the modest combined effect in vivo may result from the less-than-ideal ratio of DDP and OLE. Our further in vivo studies need to set a better drug ratio according to the in vitro data and the pharmacokinetics of DDP and OLE.

Our previous studies reported that OLE did not induce the death of hFOB1.19 normal human osteoblast cells [10]. In this study, we found that OLE alone only had a minor inhibiting effect on HK-2 normal human kidney cells at high doses and OLE combined DDP did not increase cytotoxicity in HK-2 cells compared to DDP alone. This finding is consistent with a previous study of the pharmacokinetics and metabolism of OLE in CD-1 mice, which demonstrated that the kidney retained considerably little of OLE after intravenous injection [38]. Moreover, in our in vivo study showed that OLE did not reduce the weight of nude mice, while not increased the toxicity when combined with DDP. Similar to our findings, Sreenivasan et al. reported that OLE induced apoptosis in human tumor cells but not in normal cells, such as neutrophils [39]. Calderón-Montaño et al. observed that MRC5 human lung nonmalignant cells were 10-fold resistant to OLE than A549 lung cancer cells [12]. The selectivity of OLE may arise from the relative expression of the Na+/K+-ATPase α1 and α3 subunits [8], which should be further explored in osteosarcoma.

In summary, we conclude that the combination of DDP with OLE exerts a synergistic antitumor effect in osteosarcoma in vitro and in vivo. This synergistic effect mainly depends on enhanced cell apoptosis, which partly results from the activation of the p38 MAPK/Elk-1 pathway. Further studies are needed to achieve better therapeutic effects in vivo and to investigate the potential selective mechanisms of OLE between osteosarcoma cells and normal cells.

Acknowledgements This study was supported by Grants from the National Natural Science Foundation of China (nos. 81641103 and 81802686). The authors thank the Medical Research Center of Peking University Third Hospital for the technical guidance, Dr. Zuhua Chen from Beijing Cancer Hospital for assistance with the animal studies and Dr. Yu Shi from Beijing Friendship Hospital, Capital Medical University, for help with the statistical analysis.

Compliance with ethical standards

Conflict of interest The authors declare no conflict of interest to report.

Ethical approval Animal experiment was approved by the Peking University Institutional Review Board and carried out in accordance with the approved guidelines. This article does not contain any studies with human participants performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115(7):1531–1543. https://doi.org/10.1002/cncr.24212
2. Vos HI, Coenen MJ, Guchelaar HJ, Te Loo DM (2016) The role of pharmacogenetics in the treatment of osteosarcoma. Drug Discov Today 21(11):1775–1786. https://doi.org/10.1016/j.drudis.2016.06.022
3. Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev 40(4):523–532. https://doi.org/10.1016/j.ctrv.2013.11.006
4. Patel S (2016) Plant-derived cardiac glycosides: role in heart ailments and cancer management. Biomed Pharmacother 84:1036–1041. https://doi.org/10.1016/j.biopha.2016.10.030
5. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA (2000) Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 60(14):3807–3812
6. Pan Y, Rhea P, Tan L, Cartwright C, Lee HJ, Ravoori MK, Addington C, Gagea M, Kundra V, Kim SJ, Newman RA, Yang P (2015) PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Invest New Drugs 33(2):271–279. https://doi.org/10.1007/s10637-014-0190-0
7. Garofalo S, Grimaldi A, Chece G, Porzia A, Morrone S, Mainiero F, D’Alessandro G, Esposito V, Cortese B, Di Angelantonio S, Trettel F, Limatola C (2017) The glycoside oleandrin reduces glioma growth with direct and indirect effects on tumor cells. J Neurosci 37(14):3926–3939. https://doi.org/10.1523/JNEURSCI.2296-16.2017
8. Yang P, Cartwright C, Efuet E, Hamilton SR, Carter A, Shirei Q, Newman RA (2014) Cellular location and expression of Na+, K+-ATPase α subunits affect the anti-proliferative activity of oleandrin. Mol Cancerog 53(4):253–263. https://doi.org/10.1002/mc.21968
9. Ma Y, Zhu B, Liu X, Wu H, Liu Y, Shao J, Liu Z (2015) Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/beta-catenin signaling pathway. J Exp Clin Cancer Res 34(1):115. https://doi.org/10.1186/s13046-015-0232-8
10. Ma Y, Zhu B, Song C, Liu X, Yu H, Wang P, Liu Z, Liu X (2016) Regulation of intrinsic and extrinsic apoptotic pathways in osteosarcoma cells following oleandrin treatment. Int J Mol Sci. https://doi.org/10.3390/ijms17111950
11. Felth J, Rickardson L, Rosen J, Wickstrom M, Fryknas M, Lindskog M, Bohlin L, Gulbo J (2009) Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. J Nat Prod 72(11):1969–1974. https://doi.org/10.1039/b909020m
12. Calderon-Montano JM, Burgos-Moron E, Orta ML, Mateos S, Lopez-Lazaro M (2013) A hydroalcoholic extract from the leaves of Nerium oleander inhibits glycolysis and induces selective killing of lung cancer cells. Planta Med 79(12):1017–1023. https://doi.org/10.1055/s-0032-1328715
13. Apostolou P, Toloudi M, Chatziioannou M, Ioannou E, Knocke DR, Nester J, Komiotis D, Papasotiriou I (2013) Anvirzel in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines. BMC Pharmacol Toxicol 14:18. https://doi.org/10.1186/2050-6511-14-18

14. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9(8):537–549. https://doi.org/10.1038/nrc2694

15. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehe D, Osmak M, Kaina B (2004) Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 112(6):974–985. https://doi.org/10.1002/ijc.20522

16. Zhang Y, Shen X (2007) Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res 13(10):2855–2864. https://doi.org/10.1158/1078-0432.CCR-06-2090

17. Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, Song N, Teng Y, Liu Y (2012) Down-regulation of Chib-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol 138(8):1279–1289. https://doi.org/10.1007/s00432-012-1204-4

18. Akimova OA, Tverskoi AM, Smolyaninova LV, Mengin A, Lopina OD, La J, Dulin NO, Orlov SN (2015) Critical role of the alpha1-Nat+, K+/-ATPase subunit in insensitivity of rodent cells to cytotoxic action of ouabain. Apoptosis 20(9):1200–1210. https://doi.org/10.1007/s10495-015-1144-y

19. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

20. Roos WP, Kaina B (2013) DNA damage-induced cell death: from DNA damage response and apoptosis. Cancer Lett 332(2):237–248. https://doi.org/10.1016/j.canlet.2012.01.007

21. Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C (2011) Anti-cancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther 10(2):255–268. https://doi.org/10.1158/1535-7163.mct-10-0606

22. Sun CY, Zhu Y, Li XF, Wang XQ, Tang LP, Su ZQ, Li CY, Zheng GJ, Feng B (2018) Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell lung cancer via ERK/p53 and c-met/AKT signaling pathways. Cancer Med 6(10):255–268. https://doi.org/10.1002/cam4.427

23. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Appl Pharmacol 230(70):495–516. https://doi.org/10.1016/j.taap.2006.11.012

24. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehe D, Osmak M, Kaina B (2004) Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 112(6):974–985. https://doi.org/10.1002/ijc.20522

25. Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K (2000) Cisplatin (CDPP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 45(3):199–206. https://doi.org/10.1007/s0002800050030

26. Galluzzi L, Senovilla L, Vitale I, Michaels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31(15):1869–1883. https://doi.org/10.1038/onc.2011.384

27. Chou CT, He S, Jan CR (2007) Paroxetine-induced apoptosis in human osteosarcoma cells: activation of p38 MAP kinase and caspase-3 pathways without involvement of [Ca2+]i elevation. Toxicol Appl Pharmacol 218(3):265–273. https://doi.org/10.1016/j.taap.2006.11.012

28. Zhu J, Yu W, Liu B, Wang Y, Shao J, Wang J, Xia K, Liang C, Fang W, Zhou C, Tao H (2017) Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death Dis 8(10):e3113. https://doi.org/10.1038/cddis.2017.488

29. Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakibara M, Takehara T, Fujimoto J, Horii M, Wands JR, Hayashi N (2003) Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 97(12):3017–3026. https://doi.org/10.1002/cncr.11425

30. Hsieh CJ, Kuo PL, Hsu YC, Huang YF, Tsai EM, Hsu YL (2014) Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. Free Radic Biol Med 67:159–170. https://doi.org/10.1016/j.freeradbiomed.2013.10.004

31. Roos WP, Kaina B (2013) DNA damage-induced cell death: from DNA damage response and apoptosis. Cancer Lett 332(2):237–248. https://doi.org/10.1016/j.canlet.2012.01.007

32. Shin SY, Kim CG, Lim Y, Lee YH (2011) The ETS family transcription factor ELK-1 regulates induction of the cell cycle-regulatory gene p21(Waf1/Cip1) and the BAX gene in soybean arsenite-exposed human keratinocyte HaCaT cells. J Biol Chem 286(30):26860–26872. https://doi.org/10.1074/jbc.M110.216721

33. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681. https://doi.org/10.1124/pr.58.3.10

34. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681. https://doi.org/10.1124/pr.58.3.10

35. Tolcher AW, Mayer LD (2018) Improving combination cancer therapy: the CombiPlex(R) development platform. Future Oncol 14(13):1317–1332. https://doi.org/10.2217/fon-2017-0607

36. Si D, Madden TL, Johansen F, Felix E, Ho DH, Newman RA (2002) Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander. J Exp Ther Oncol 2(5):278–285

37. Sreenivasan Y, Sarkar A, Manna SK (2003) Oleandrin suppresses activation of nuclear transcription factor-xB and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol 66(11):2223–2239. https://doi.org/10.1016/j.bcp.2003.07.010